The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 10, 2023
Filed:
Dec. 16, 2019
Applicant:
The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US);
Inventors:
Robert Lowsky, Stanford, CA (US);
Edgar George Engleman, Atherton, CA (US);
Samuel Strober, Stanford, CA (US);
Assignee:
The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/713 (2006.01); A61K 41/00 (2020.01); A61K 45/06 (2006.01); A61N 1/30 (2006.01); A61B 18/08 (2006.01); A61N 7/00 (2006.01); A61B 18/14 (2006.01); C12N 15/117 (2010.01); A61N 5/10 (2006.01); A61B 18/00 (2006.01); A61M 37/00 (2006.01); A01K 67/027 (2006.01);
U.S. Cl.
CPC ...
A61M 37/0092 (2013.01); A01K 67/0271 (2013.01); A61K 31/713 (2013.01); A61K 41/00 (2013.01); A61K 45/06 (2013.01); A61N 1/30 (2013.01); A01K 2207/12 (2013.01); A01K 2207/35 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0331 (2013.01); A61B 18/08 (2013.01); A61B 18/14 (2013.01); A61B 2018/00577 (2013.01); A61M 2037/0007 (2013.01); A61N 5/10 (2013.01); A61N 7/00 (2013.01); A61N 2005/1098 (2013.01); C12N 15/117 (2013.01); C12N 2310/17 (2013.01); C12N 2310/315 (2013.01); C12N 2320/31 (2013.01);
Abstract
Residual, refractory or relapsed cancer is treated by immunostimulation in the presence of allogeneic immune effector cells, optimally in combination with radiation therapy. The methods of the disclosure induce a systemic allogeneic anti-tumor immune response that results in tumor regression in untreated sites of disease, i.e. non-injected, non-irradiated, etc.